Please assess the completion status of the following clinical trial:

Trial Title: Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants (\< 1 year corrected gestational age) Infants with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) will be eligible for treatment in the immediate post-operative period.~* Infants with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for \>50% of calories by PN (independent of the length of remnant small intestine).~* Children (\> 1 year corrected gestational age) Children with a requirement for \>30% of calories by PN more than 1 year (365) days post surgery will be eligible.~Exclusion Criteria:~* Significant extra-intestinal disease (e.g., grade IV intraventricular hemorrhage, severe hypoxic encephalopathy);~* Significant cardiovascular, hemodynamic or respiratory instability, as noted by 1) the requirement for dopamine \> 4 mcg/kg/min, 2) high frequency ventilatory support, 3) extracorporeal membrane oxygenation.~* Hepatic disease defined as direct bilirubin \> 100 umol/L (5.2 mg/dL)~* Renal disease defined as BUN \> 80 or creatinine \> 90 μmol/L (1.5 mg/dL)~* Inborn errors of metabolism necessitating protein restriction or other special diet;~* Ongoing sepsis syndrome, as noted by refractory hypotension, thrombocytopenia, acidosis, and/or bacteremia.~* Primary motility defect such as intestinal pseudo-obstruction.~* Absorptive defects (such as microvillus inclusion disease)~* Females who are post-pubertal must agree to comply with measures to prevent pregnancy during the study phase.~* Coagulopathy which precludes the use of subcutaneous injections.~* Allergy to GLP-2 or any of the constituent of the GLP-2 IC-115 preparation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intestinal Failure in children (>1 year) (Type: EXPERIMENTAL): Children requiring parenteral nutrition for \>30% of calories more than 1 year (365) days post surgery will be eligible for treatment with Glucagon-like peptide 2 (20 ug/kg/day) for 6 weeks
- GLP-2 in Infants (<1 year of age) (Type: EXPERIMENTAL): Infants under one year of age with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) or with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for \>50% of calories by PN (independent of the length of remnant small intestine) will be eligible for treatment with Glucagon-like peptide 2, at a dose of 5, 10 or 20 ug/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).